Literature DB >> 32122549

CRISPR technology for immuno-oncology applications.

Jianbin Wang1, Vitaly Balan2, Francesco Marincola2.   

Abstract

Emergency of the CRISPR technology, a new genome editing tool, revolutionized the biomedical research field in the past 6 years. At the same time, recent advances in cancer immunotherapy reinvigorated our hope to cure most if not all cancer patients with further development of various treatment options. A combination of the CRISPR technology with immuno-oncology research will undoubtedly accelerate the development of new cancer therapies. This review will focus on the CRISPR system and its applications in immune-oncology including identification of immune-oncology gene targets, generation of cancer animal models, and enabling better cell design and manufacture for adoptive cellular therapies.
© 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CAR-T; CRISPR; Cancer; Cas9; Immuno-oncology; Immunotherapy; dCas9; sgRNA

Mesh:

Year:  2019        PMID: 32122549     DOI: 10.1016/bs.mie.2019.05.018

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  1 in total

Review 1.  Targeting Cancer with CRISPR/Cas9-Based Therapy.

Authors:  Katarzyna Balon; Adam Sheriff; Joanna Jacków; Łukasz Łaczmański
Journal:  Int J Mol Sci       Date:  2022-01-05       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.